Riskpilot← Back to searchSign inGet full accessDiaSystem Vet AB
ABActiveOrg 5592541485Ekhagsringen 17Wholesale of chemical products · NACE 4685Est. 20201-4 employees
Revenue 2024
SEK 16,3M
+7% vs 2023
EBITDA margin
25.7%
-11% vs 2023
Equity ratio
42.2%
Financial strength
Net profit 2024
SEK 2,3M
-14% vs 2023
| Revenue | SEK 16,3M | +7% |
| EBITDA | SEK 4,2M | -11% |
| Net profit | SEK 2,3M | -14% |
| Total assets | SEK 11M | +54% |
| Equity | SEK 4,6M | +65% |
| Employees | — | — |
Legal name
DiaSystem Vet AB
Org number
5592541485
Legal form
Aktiebolag
NACE code
4685 · Wholesale of chemical products
Founded
29 april 2020
Share capital
SEK 30 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget ska bedriva handel med diagnostika och analys-instrument samt tillverkning av diagnostika samt bedriva därmed förenlig verksamhet.
Address
Ekhagsringen 17
Email
info@diasystemvet.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 832 | 8 961 | 11 195 | 15 293 | 16 324 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 639 | 3 101 | 2 049 | 4 718 | 4 199 |
| Depreciation & amort. | −147 | −217 | −217 | −217 | −226 |
| EBIT | 492 | 2 884 | 1 832 | 4 501 | 3 973 |
| Net financials | −3 | −3 | −5 | −14 | 63 |
| Profit before tax | 310 | 2 126 | 1 385 | 3 411 | 2 954 |
| Tax | −68 | −440 | −295 | −715 | −626 |
| Net profit | 242 | 1 686 | 1 090 | 2 696 | 2 328 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 114 | 4 983 | 4 357 | 7 126 | 10 988 |
| Equity | 272 | 1 958 | 1 148 | 2 814 | 4 642 |
| Long-term debt | 1 000 | 800 | 0 | 0 | 0 |
| Short-term debt | 663 | 1 292 | 1 835 | 1 861 | 2 812 |
| Total debt | 1 663 | 2 092 | 1 835 | 1 861 | 2 812 |
EBITDA margin
25.7%
This company
15.8%
Market median
+63% vs market
20202024
Equity ratio
42.2%
This company
38.2%
Market median
+10% vs market
20202024
Return on equity
50.2%
This company
18.4%
Market median
+173% vs market
20202024
Net profit margin
14.3%
This company
8.1%
Market median
+77% vs market
20202024
Asset turnover
1.49×
This company
1.12×
Market median
+33% vs market
20202024
Debt / equity
1.37×
This company
0.62×
Market median
-121% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-04-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PA | Audit | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Deputy Board Member | 2024 | |
| Former (3) | ||
| Chairman | 2020 – 2024 | |
| Deputy Board Member | 2020 – 2024 | |
| Board of Directors | 2022 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
AREE Invest AB
DiaSystem Vet AB Board members of DiaSystem Vet AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Pär Anders Tomas Claesson | Audit | 0 companies |
| Robert Kjell Rademacher | Board of Directors | 0 companies |
| Max Peter Erwin Werner Rademacher | Chairman | 0 companies |
| Piroska Rademacher | Deputy Board Member | 0 companies |
| Åsa Ingela Yvonne Andersson | Deputy Board Member | 0 companies |
| Johan Peter Mouantri | Board of Directors | 0 companies |